Cargando…

Impact of probiotics use on clinical outcomes of immune checkpoint inhibitors therapy in cancer patients

BACKGROUND: Dysbiosis of the gut microbiota can lead to impaired therapeutic effect of immune checkpoint inhibitors (ICIs). This study aimed to investigate the use of probiotics on the clinical outcomes of cancer patients receiving ICIs therapy. METHOD: PubMed, EMBASE, and the Cochrane Library datab...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wan, Luying, Wu, Chunlan, Wu, Qin, Luo, Shuimei, Liu, Junjin, Xie, Xianhe
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2022
Materias:	RESEARCH ARTICLES
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9883533/ https://www.ncbi.nlm.nih.gov/pubmed/35770869 http://dx.doi.org/10.1002/cam4.4994

Ejemplares similares

Prognostic Value of Lymphocyte-to-Monocyte Ratio (LMR) in Cancer Patients Undergoing Immune Checkpoint Inhibitors
por: Wan, Luying, et al.
Publicado: (2022)

The impact of anti-tumor approaches on the outcomes of cancer patients with COVID-19: a meta-analysis based on 52 cohorts incorporating 9231 participants
por: Wu, Qing, et al.
Publicado: (2022)

Evaluation on efficacy and safety of tyrosine kinase inhibitors plus radiotherapy in NSCLC patients with brain metastases
por: Luo, Shuimei, et al.
Publicado: (2015)

Efficacy and safety of angiogenesis inhibitors in small-cell lung cancer
por: Lin, Heng, et al.
Publicado: (2016)

Efficacy and safety of immune checkpoint inhibitors in Proficient Mismatch Repair (pMMR)/ Non-Microsatellite Instability-High (non-MSI-H) metastatic colorectal cancer: a study based on 39 cohorts incorporating 1723 patients
por: Wu, Qing, et al.
Publicado: (2023)

Hyperthermia combined with immune checkpoint inhibitor therapy: Synergistic sensitization and clinical outcomes
por: Liu, Pengyuan, et al.
Publicado: (2022)

The correlation between probiotic use and outcomes of cancer patients treated with immune checkpoint inhibitors
por: Zhang, Lilong, et al.
Publicado: (2022)

Upregulation of KHDC1L promotes the proliferation and inhibits apoptosis in head and neck squamous cell carcinoma
por: Zhang, Qi, et al.
Publicado: (2023)

Comprehensive Analysis Reveals PTK6 as a Prognostic Biomarker Involved in the Immunosuppressive Microenvironment in Breast Cancer
por: Wang, Lili, et al.
Publicado: (2022)

Fatal toxic effects related to EGFR tyrosine kinase inhibitors based on 53 cohorts with 9,569 participants
por: Xie, Xianhe, et al.
Publicado: (2020)

Impact of corticosteroid therapy on the outcomes of hepatocellular carcinoma treated with immune checkpoint inhibitor therapy
por: Pinato, David J, et al.
Publicado: (2020)

CDK4/6 Inhibitor Palbociclib Amplifies the Radiosensitivity to Nasopharyngeal Carcinoma Cells via Mediating Apoptosis and Suppressing DNA Damage Repair
por: Xie, Xianhe, et al.
Publicado: (2019)

Antibiotic therapy and outcome from immune-checkpoint inhibitors
por: Pinato, David J., et al.
Publicado: (2019)

Tumor fitness, immune exhaustion and clinical outcomes: impact of immune checkpoint inhibitors
por: Bubie, Adrian, et al.
Publicado: (2020)

Efficacy and Toxicity of Low-Dose versus Conventional-Dose Chemotherapy for Malignant Tumors: a Meta-Analysis of 6 Randomized Controlled Trials
por: Xie, Xianhe, et al.
Publicado: (2017)

Efficacy and safety of antitumor agents plus radiotherapy compared with radiotherapy alone for brain metastases from lung cancer
por: Lin, Heng, et al.
Publicado: (2017)

Clinical Characteristics and Outcomes in Immune Checkpoint Inhibitor Therapy-Associated Myocarditis
por: Thakker, Ravi A., et al.
Publicado: (2021)

Development of fluorescence-labeled antibody for immune checkpoint inhibitor using engineered probiotics
por: Namai, Fu, et al.
Publicado: (2023)

The Impact of Tregs on the Anticancer Immunity and the Efficacy of Immune Checkpoint Inhibitor Therapies
por: González-Navajas, Jose M., et al.
Publicado: (2021)

Drug therapy for myocarditis induced by immune checkpoint inhibitors
por: Wu, Yihao, et al.
Publicado: (2023)

Time Rules the Efficacy of Immune Checkpoint Inhibitors in Photodynamic Therapy
por: Wu, Qinghua, et al.
Publicado: (2022)

Clinical outcomes of immune checkpoint inhibitor therapy for advanced lung adenosquamous carcinoma
por: Wei, Jingwen, et al.
Publicado: (2023)

Immune checkpoint inhibitors in cancer therapy
por: Webb, Eika S., et al.
Publicado: (2018)

Immune Checkpoint Inhibitors for the Therapy of Thymoma
por: Quilez, Alicia, et al.
Publicado: (2020)

Immune Checkpoint Inhibitors in Cancer Therapy
por: Shiravand, Yavar, et al.
Publicado: (2022)

Impact of cancer evolution on immune surveillance and checkpoint inhibitor response
por: Wu, Yin, et al.
Publicado: (2022)

The impact of antibiotic use on clinical features and survival outcomes of cancer patients treated with immune checkpoint inhibitors
por: Zhou, Jiaxin, et al.
Publicado: (2022)

The correlation between programmed death-ligand 1 expression and driver gene mutations in NSCLC
por: Yang, Haitao, et al.
Publicado: (2017)

Systemic Blood Immune Cell Populations as Biomarkers for the Outcome of Immune Checkpoint Inhibitor Therapies
por: Hernandez, Carlos, et al.
Publicado: (2020)

The landscape of immune checkpoint inhibitor therapy in advanced lung cancer
por: Wang, Chengdi, et al.
Publicado: (2021)

The Impact of Concomitant Proton Pump Inhibitors Therapy on Clinical Outcome of Cancer Patients Treated With Immune Checkpoint Inhibitors: A Meta-analysis
por: Cao, Xing, et al.
Publicado: (2023)

Immune Checkpoint Inhibitors in HBV-Caused Hepatocellular Carcinoma Therapy
por: Zhang, Jin, et al.
Publicado: (2023)

Immune Checkpoint Inhibitor Therapy Associated Hypophysitis
por: Mahzari, Moeber, et al.
Publicado: (2015)

Phytochemicals in Cancer Immune Checkpoint Inhibitor Therapy
por: Lee, Juwon, et al.
Publicado: (2021)

Advanced Research on Immune Checkpoint Inhibitor Therapy
por: Imai, Hisao, et al.
Publicado: (2022)

Immune checkpoint inhibitor therapy for hepatocellular carcinoma
por: Ramai, Daryl, et al.
Publicado: (2022)

Immune Checkpoint Inhibitor Therapy in Neuroendocrine Tumors
por: Gubbi, Sriram, et al.
Publicado: (2022)

The Role of Immune Checkpoint Inhibitors in Cancer Therapy
por: Basudan, Ahmed M.
Publicado: (2022)

Clinical Impact of Checkpoint Inhibitors as Novel Cancer Therapies
por: Shih, Kent, et al.
Publicado: (2014)

Modelling of Immune Checkpoint Network Explains Synergistic Effects of Combined Immune Checkpoint Inhibitor Therapy and the Impact of Cytokines in Patient Response
por: Kondratova, Maria, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_krlq6f8dbt0nbsn8qp82c3sn64